Darren Sherman Sells 15,000 Shares of Orchestra BioMed (NASDAQ:OBIO) Stock

Key Points

• Insider sale: Darren Sherman sold 15,000 Orchestra BioMed shares at an average price of $4.09, worth $61,350, under a pre-arranged Rule 10b5-1 plan. He continues to own 1,154,327 shares.
• Stock performance: OBIO recently traded at $4.27, within its 52-week range of $2.20 to $5.42. The company has a $255.69 million market capitalization and reported a quarterly loss of $0.33 per share, better than analysts’ estimate.
• Analyst outlook: Analysts maintain a “Moderate Buy” consensus with an average price target of $13.60, although ratings include both buy and sell recommendations. Institutional investors own approximately 53.2% of the company.

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) insider Darren Sherman sold 15,000 shares of Orchestra BioMed stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $4.09, for a total value of $61,350.00. Following the completion of the sale, the insider directly owned 1,154,327 shares of the company's stock, valued at approximately $4,721,197.43. This trade represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Darren Sherman also recently made the following trade(s):

• On Monday, June 1st, Darren Sherman sold 15,000 shares of Orchestra BioMed stock. The shares were sold at an average price of $3.87, for a total transaction of $58,050.00.

Orchestra BioMed Stock Performance

NASDAQ:OBIO traded up $0.15 on Tuesday, reaching $4.27. 151,794 shares of the company's stock were exchanged, compared to its average volume of 255,775. The company has a debt-to-equity ratio of 0.35, a current ratio of 7.03 and a quick ratio of 7.01. The firm has a market cap of $255.69 million, a price-to-earnings ratio of -4.40 and a beta of 0.50. Orchestra BioMed Holdings, Inc. has a 52 week low of $2.20 and a 52 week high of $5.42. The stock has a fifty day simple moving average of $3.95 and a 200-day simple moving average of $4.10.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.07. The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.92 million. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. As a group, sell-side analysts predict that Orchestra BioMed Holdings, Inc. will post -1.47 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on OBIO. Wall Street Zen lowered Orchestra BioMed from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. Barclays raised their target price on Orchestra BioMed from $12.00 to $13.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 13th. B. Riley Financial reduced their target price on Orchestra BioMed from $12.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, May 19th. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Orchestra BioMed in a research report on Thursday, May 14th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Orchestra BioMed in a report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Orchestra BioMed presently has an average rating of "Moderate Buy" and an average target price of $13.60.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in OBIO. Alyeska Investment Group L.P. bought a new position in Orchestra BioMed in the 3rd quarter worth about $3,386,000. Pathstone Holdings LLC purchased a new stake in shares of Orchestra BioMed in the 3rd quarter valued at about $2,495,000. Vanguard Group Inc. boosted its position in shares of Orchestra BioMed by 28.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company's stock valued at $3,675,000 after acquiring an additional 324,558 shares during the last quarter. Simplify Asset Management Inc. bought a new stake in shares of Orchestra BioMed during the 1st quarter valued at about $932,000. Finally, 683 Capital Management LLC purchased a new position in shares of Orchestra BioMed during the fourth quarter worth about $847,000. Institutional investors own 53.20% of the company's stock.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc NASDAQ: OBIO is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.